See the DrugPatentWatch profile for Rystiggo
Rystiggo Mechanism of Action
Rystiggo, also known as fingolimod hydrochloride, is a sphingosine-1-phosphate (S1P) receptor modulator. Its mechanism of action involves selectively binding to S1P receptors on lymphocytes, which are a type of white blood cell [1]. By binding to these receptors, Rystiggo prevents lymphocytes from migrating from lymph nodes into the central nervous system (CNS) [1]. This reduction in lymphocyte infiltration into the CNS is believed to be the primary way Rystiggo exerts its therapeutic effect in certain neurological conditions.
How Does Rystiggo Prevent Lymphocyte Movement?
Rystiggo works by downregulating S1P receptors on lymphocytes [2]. The S1P receptor is crucial for lymphocytes to exit lymph nodes and enter circulation, eventually reaching tissues like the brain. When Rystiggo binds to these receptors, it causes them to be internalized and degraded, effectively reducing the number of functional S1P receptors on the lymphocyte surface [2]. This leads to a functional "trapping" of lymphocytes within the lymph nodes, thereby decreasing their presence in the CNS.
What Neurological Conditions Does Rystiggo Treat?
Rystiggo is indicated for the treatment of adults with relapsing forms of multiple sclerosis (MS), to decrease the frequency of clinical relapses and to slow the accumulation of disability [3]. Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
When Does Rystiggo Patent Expiration Occur?
Information regarding the specific patent expiration dates for Rystiggo is available through specialized patent tracking services. DrugPatentWatch.com tracks patent information for numerous pharmaceuticals [4].
What Are the Potential Risks and Side Effects of Rystiggo?
Treatment with Rystiggo carries several risks, including serious infections, bradycardia (slow heart rate), effects on vision (macular edema), liver enzyme elevations, and fetal harm [3]. Patients may also experience changes in blood pressure and respiratory infections [3]. Due to these risks, patients require careful monitoring during and after treatment.
Are There Alternatives to Rystiggo for Multiple Sclerosis?
Yes, several other disease-modifying therapies (DMTs) are available for multiple sclerosis, which work through different mechanisms [5]. These include injectable medications, oral medications, and infusions. The choice of treatment depends on the specific type and severity of MS, as well as individual patient factors and physician recommendations [5].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/